- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06081426
Untersuchung neurobiologischer Mechanismen, die der therapeutischen Wirkung der ketogenen Ernährung bei bipolarer Störung (BD) zugrunde liegen
Aufklärung neurobiologischer Mechanismen, die der therapeutischen Wirkung der ketogenen Ernährung bei bipolarer Störung (BD) zugrunde liegen: eine multidisziplinäre mechanistische Studie
The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The investigators hypothesize that a ketogenic diet will enhance levels of the ketone body β-Hydroxybutyrate (beta OHB), resulting in reduced mania/hypomania severity and predisposition to mania/hypomania in individuals with BD. To test this hypothesis in depth, the investigators will use a novel, multidisciplinary mechanistic study using multimodal neuroimaging, peripheral markers of mitochondrial metabolism, and participant-derived induced pluripotent stem cell (iPSC)-derived organoids.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Jill Morris-Tillman
- Telefonnummer: 412-383-8206
- E-Mail: morristillmanje@upmc.edu
Studienorte
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- Rekrutierung
- University of Pittsburgh Medical Center
-
Kontakt:
- Jill Morris-Tillman
- Telefonnummer: 412-383-8206
- E-Mail: morristillmanje@upmc.edu
-
Hauptermittler:
- Mary L Phillps, MD, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
All participants:
- 18-40 years of age
- Not following a ketogenic diet
BD hypomanic group (n=30):
- Meeting sex proportion: 50% female
- Meeting diagnosis proportion: 50:50% Bipolar I: Bipolar II (BDI:II) (Diagnostic and Statistical Manual of Mental Disorders 5; DSM-5)
- Score greater than 10 on the Young Mania Rating Scale score(YMRS)
- BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
- Has a primary care provider (if enrolled in ketogenic diet phase)
BD euthymic group (n=30):
- Meeting sex proportion: 50% female
- Meeting diagnosis proportion: 50:50% BDI:II (DSM-5)
- Score less than or equal to 10 on YMRS
- BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
- Has a primary care provider (if enrolled in ketogenic diet phase)
Healthy Control (HC) Group (n=30):
- Sex matched with BD groups
- No psychiatric history
Exclusion Criteria:
All participants:
- Not between 18-40 years of age
- History of head injury, neurological, pervasive developmental disorder (e.g. autism), systemic medical disease and treatment (medical records, participant report)
- Mini-Mental State Examination score (cognitive state) <24
- Premorbid National Adult Reading Test Intelligent Quotient (NAART IQ) estimate<85
- Visual disturbance: <20/40 Snellen visual acuity
- History of alcohol/substance use disorder (SUD; all substances, including nicotine), and/or illicit substance use (except cannabis) over the last 6 months (SCID-5). Note: lifetime/present cannabis use (at non-abuse (<3 times in the past month) and non SUD levels) will be allowed, given its common usage in BD and young adults. Cannabis SUD over the last 6 months will not be allowed. Urine tests on scan days will exclude current illicit substance use (except cannabis). Salivary alcohol tests on scan days will exclude intoxicated individuals
- MRI exclusion: metallic objects, e.g., surgical implants; claustrophobia; positive pregnancy test for females or self-report pregnancy
- Unable to understand English
- Conditions related to the pancreas, liver, thyroid or gallbladder.
- Taking anticoagulants and/or those with blood dyscrasias (illnesses) who have coagulation disorders (eg, hemophilia) because of the ketomojo finger stick blood tests
- Scoring 3 or higher on positive symptom factor questions on the Positive and Negative Syndrome Scale (PANSS) questionnaire (indicative of psychotic symptoms)
- Currently following a ketogenic diet
- Head circumference larger than 24 inches (62cm) and/or chest circumference larger than 55 inches (139 cm)
- Taken medications for diabetes and weight loss (e.g., Wegovy, Orlistat) in the past month
BD hypomanic group:
- Must be meeting sex proportions: not 50% female
- Must be meeting diagnosis proportions: not 50:50% BDI:II (DSM-5)
- Diagnosis of BD in a manic or euthymic episode
- Score 10 or lower on the Young Mania Rating Scale score(YMRS)
- Using psychotropic medications other than those allowed in inclusion criteria
- Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
- Does not have a primary care provider (if enrolled in ketogenic diet phase)
BD euthymic group:
- Not meeting sex proportion: not 50% female
- Not meeting diagnosis proportion: not 50:50% BDI:II
- Diagnosis of BD in a depressive, hypomanic, or manic episode
- Score greater than 10 on YMRS
- Using psychotropic medications other than those allowed in inclusion criteria
- Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
- Does not have a primary care provider (if enrolled in ketogenic diet phase)
Healthy Control (HC) Group
- Not sex-matched with BD groups
- Has psychiatric history
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: 1st phase Non-ketogenic Diet / 2nd phase Ketogenic Diet
Participants with Bipolar Disorder will consume a non-ketogenic diet for the first phase of the study and then a ketogenic diet for the second phase of the study |
Consuming a non-ketogenic diet Consuming a ketogenic diet |
|
Experimental: 1st phase Ketogenic Diet / 2nd phase Non-ketogenic Diet
Participants with Bipolar Disorder will consume a ketogenic diet for the first phase of the study and then a non-ketogenic diet for the second phase of the study |
Consuming a non-ketogenic diet Consuming a ketogenic diet |
|
Sonstiges: No diet
Participants without Bipolar Disorder will not participate in the diet phases of the study |
Participants without Bipolar Disorder will not participate in the diet phases of the study |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Blood oxygen level-dependent (BOLD) signal at Scan 1
Zeitfenster: Baseline Scan 1 (all participants)
|
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity |
Baseline Scan 1 (all participants)
|
|
Blood oxygen level-dependent (BOLD) signal at Scan 2
Zeitfenster: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Blood oxygen level-dependent (BOLD) signal at Scan 3
Zeitfenster: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Manic symptoms at Scan 1
Zeitfenster: Baseline Scan 1 (all participants)
|
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome) |
Baseline Scan 1 (all participants)
|
|
Manic symptoms at Scan 2
Zeitfenster: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome) |
Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Manic symptoms at Scan 3
Zeitfenster: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome) |
Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting Glucose at Baseline
Zeitfenster: Baseline (all participants)
|
Fasting glucose blood levels |
Baseline (all participants)
|
|
Fasting lipids at Baseline
Zeitfenster: Baseline (all participants)
|
Fasting lipid blood levels |
Baseline (all participants)
|
|
Fasting hepatic function panel at Baseline: total protein
Zeitfenster: Baseline (all participants)
|
Fasting levels of total protein in the blood |
Baseline (all participants)
|
|
Fasting hepatic function panel at Baseline: albumin
Zeitfenster: Baseline (all participants)
|
Fasting levels of albumin in the blood |
Baseline (all participants)
|
|
Fasting hepatic function panel at Baseline: bilirubin
Zeitfenster: Baseline (all participants)
|
Fasting levels of bilirubin in the blood |
Baseline (all participants)
|
|
Fasting hepatic function panel at Baseline: liver enzyme
Zeitfenster: Baseline (all participants)
|
Fasting levels of liver enzyme in the blood |
Baseline (all participants)
|
|
Fasting Glucose at halfway point through first dietary phase
Zeitfenster: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting glucose blood levels |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting lipids at halfway point through first dietary phase
Zeitfenster: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting lipid blood levels |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through first dietary phase: total protein
Zeitfenster: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of total protein in the blood |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through first dietary phase: albumin
Zeitfenster: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of albumin in the blood |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through first dietary phase: bilirubin
Zeitfenster: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of bilirubin in the blood |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through first dietary phase: liver enzyme
Zeitfenster: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of liver enzyme in the blood |
Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting Glucose at end of first dietary phase
Zeitfenster: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting glucose blood levels |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting lipids at end of first dietary phase
Zeitfenster: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting lipid blood levels |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of first dietary phase: total protein
Zeitfenster: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of total protein in the blood |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of first dietary phase: albumin
Zeitfenster: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of albumin in the blood |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of first dietary phase: bilirubin
Zeitfenster: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of bilirubin in the blood |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of first dietary phase: liver enzyme
Zeitfenster: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of liver enzyme in the blood |
End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting Glucose at halfway point through second dietary phase
Zeitfenster: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting glucose blood levels |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting lipids at halfway point through second dietary phase
Zeitfenster: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting lipid blood levels |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through second dietary phase: total protein
Zeitfenster: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of total protein in the blood |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through second dietary phase: albumin
Zeitfenster: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of albumin in the blood |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through second dietary phase: bilirubin
Zeitfenster: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of bilirubin in the blood |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at halfway point through second dietary phase: liver enzyme
Zeitfenster: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
Fasting levels of liver enzyme in the blood |
Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
|
|
Fasting Glucose at end of second dietary phase
Zeitfenster: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting glucose blood levels |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting lipids at end of second dietary phase
Zeitfenster: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting lipids blood levels |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of second dietary phase: total protein
Zeitfenster: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of total protein in the blood |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of second dietary phase: albumin
Zeitfenster: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of albumin in the blood |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of second dietary phase: bilirubin
Zeitfenster: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of bilirubin in the blood |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Fasting hepatic function at end of second dietary phase: liver enzyme
Zeitfenster: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Fasting levels of liver enzyme in the blood |
End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Gamma-aminobutyric acid (GABA) at Baseline
Zeitfenster: Baseline Scan 1 (all participants)
|
Gamma-aminobutyric acid (GABA) concentrations in the brain |
Baseline Scan 1 (all participants)
|
|
Glutamate at Baseline
Zeitfenster: Baseline Scan 1 (all participants)
|
Glutamate concentrations in the brain |
Baseline Scan 1 (all participants)
|
|
Lactate at Baseline
Zeitfenster: Baseline Scan 1 (all participants)
|
Lactate concentrations in the brain |
Baseline Scan 1 (all participants)
|
|
Gamma-aminobutyric acid (GABA) at end of first dietary phase
Zeitfenster: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Gamma-aminobutyric acid (GABA) concentrations in the brain |
Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Glutamate at end of first dietary phase
Zeitfenster: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Glutamate concentrations in the brain |
Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Lactate at end of first dietary phase
Zeitfenster: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Lactate concentrations in the brain |
Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Gamma-aminobutyric acid (GABA) at end of second dietary phase
Zeitfenster: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Gamma-aminobutyric acid (GABA) concentrations in the brain |
Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Glutamate at end of second dietary phase
Zeitfenster: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Glutamate concentrations in the brain |
Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Lactate at end of second dietary phase
Zeitfenster: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Lactate concentrations in the brain |
Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Average total sleep time during Ketogenic vs Normal diet
Zeitfenster: Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals
|
Total sleep time will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home. |
Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals
|
|
Average rest-activity rhythm interdaily stability during Ketogenic vs Normal diet
Zeitfenster: Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.
|
Rest-activity rhythm interdaily stability will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home |
Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.
|
|
Ecological momentary assessments (EMA) during the first dietary phase: Mood monitoring
Zeitfenster: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood |
The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the first dietary phase: Energy monitoring
Zeitfenster: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy |
The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the first dietary phase: Suicidality monitoring
Zeitfenster: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans |
The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the second dietary phase: Mood monitoring
Zeitfenster: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood |
The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the second dietary phase: Energy monitoring
Zeitfenster: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy |
The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
|
Ecological momentary assessments (EMA) during the second dietary phase: Suicidality monitoring
Zeitfenster: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans |
The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Mary Phillips, MD, University of Pittsburgh
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- STUDY23080048
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Informed consent will be collected from study participants that allows for broad sharing of participants' de-identified data. Data transfer procedures will be in accordance with all Institutional Review Board guidelines and federal regulations including HIPAA (Health Insurance Portability and Accountability Act of 1996).
IPD-Sharing-Zeitrahmen
The principal investigators (PIs) reserve the right to publish on the stated aims in a timely manner. Data will be available for addressing other research questions (i.e. which are not described in funded/pending grants) as soon as the data have been checked for accuracy (a period which will be no later than one year after the completion of each assessment). After the study has ended, the study investigators will continue to test the stated aims, but will also continue to solicit collaborations with outside researchers and to consider data requests in a timely manner.
IPD-Sharing-Zugriffskriterien
Outside investigators must submit a 1)proposal of the study aims, hypotheses, variables/constructs, analytic approach, and estimated duration of the proposed research; 2)resume, qualifications, source of financial support, and conflict of interest statement; 3)sign a data-sharing agreement and confidentiality statement that stipulates using the data for the stated research purposes only, securing the data using appropriate computer technology, not manipulating the data in order to identify participants, acknowledging the grant that supported data collection and management in publications/presentations, and destroying or returning the data after analyses are complete; 4)obtain approval from their Institutional Review Board, and along with other staff members who have access to the data, submit certificates of the University of Pittsburgh Education and Certification Program in Research Practice Fundamentals or provide written documentation of similar human subjects protection training.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .